A Double-blind, Randomised, Incomplete Block, Crossover, Placebo-controlled, Dose-response Study to Assess Bronchial Hyperresponsiveness and Airway Inflammation Effects of FlutiForm pMDI Low and High Dose in Adult Subjects With Mild to Moderate Asthma.
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2013
At a glance
- Drugs Formoterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Pharmacodynamics
- Sponsors Mundipharma International
- 08 Aug 2012 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 08 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2012 Planned end date changed from 1 Nov 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.